Translational Development Acquisition Corp
NASDAQ:TDAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Translational Development Acquisition Corp
Total Equity
Translational Development Acquisition Corp
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Translational Development Acquisition Corp
NASDAQ:TDAC
|
Total Equity
$175.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WP Carey Inc
NYSE:WPC
|
Total Equity
$8.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
AltC Acquisition Corp
NYSE:OKLO
|
Total Equity
$1.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Annaly Capital Management Inc
NYSE:NLY
|
Total Equity
$16.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Ares Capital Corp
NASDAQ:ARCC
|
Total Equity
$14.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
SoFi Technologies Inc
NASDAQ:SOFI
|
Total Equity
$10.5B
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Translational Development Acquisition Corp
Glance View
Translational Development Acquisition Corp is a US-based company operating in industry. The company is headquartered in New York City, New York. The company went IPO on 2024-12-23. Translational Development Acquisition Corp. is a blank check company. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The firm has not selected any specific business combination target, and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The firm may pursue an acquisition opportunity in any business, industry, sector or geographical location. The firm intends to focus on industries that complement its management team’s background, and to capitalize on the ability of its management team to identify and acquire a business. The firm has neither engaged in any operations nor generated any revenues.
See Also
What is Translational Development Acquisition Corp's Total Equity?
Total Equity
175.1m
USD
Based on the financial report for Dec 31, 2025, Translational Development Acquisition Corp's Total Equity amounts to 175.1m USD.
What is Translational Development Acquisition Corp's Total Equity growth rate?
Total Equity CAGR 1Y
4%
Over the last year, the Total Equity growth was 4%.
